CLINICAL TRIALS PROFILE FOR MOLNUPIRAVIR
✉ Email this page to a colleague
Clinical Trials for Molnupiravir
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04392219 ↗ | COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers | Completed | Ridgeback Biotherapeutics, LP | Phase 1 | This is a First In Human study designed to assess the safety, tolerability and pharmacokinetics of EIDD-2801 in healthy human volunteers. |
| NCT04405570 ↗ | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | Completed | Ridgeback Biotherapeutics, LP | Phase 2 | This is a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 versus placebo as measured by infectious virus detection in symptomatic adult outpatients with COVID-19 |
| NCT04405739 ↗ | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | Recruiting | Ridgeback Biotherapeutics, LP | Phase 2 | Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19. |
| NCT04575584 ↗ | Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) | Terminated | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 | This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29. |
| NCT04575597 ↗ | Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 | This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29 |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Molnupiravir
Condition Name
Clinical Trial Locations for Molnupiravir
Trials by Country
Clinical Trial Progress for Molnupiravir
Clinical Trial Phase
Clinical Trial Sponsors for Molnupiravir
Sponsor Name
